Awakn Life Sciences has announced a Phase III trial to explore the effects of ketamine-assisted therapy in the treatment of alcohol use disorder (AUD).
Status: Planned
Start date: 2023-05-01
Phase III
Blinded
280 participants
Interventional
This study will investigate whether psilocybin administered under supportive conditions can reduce illicit opioid use and improve quality of life in individuals with Opioid Use Disorder (OUD) in Methadone Maintenance Treatment (MMT) who are concurrently using other opioids illicitly.
Status: Not yet recruiting
Start date: 2022-02-16
Phase II
Blinded
92 participants
Interventional
96 recently detoxified alcoholics will be randomized to receive either 3 sessions ketamine (0.8 mg/kg IV over 45 minutes) or placebo plus manualised psychological therapy, or 3 sessions of ketamine or placebo plus simple psychoeducation.
Status: Completed
Start date: 2016-10-10
Phase II
Blinded
96 participants
Interventional
The purpose of the study is to examine whether an investigational medication called ketamine is able to improve treatment outcomes for concurrent opioid addiction and depression when used in conjunction with buprenorphine treatment.
Status: Recruiting
Start date: 2020-12-17
Phase II
Blinded
30 participants
Interventional
This project aims to evaluate the potential rapid and sustained antisuicidal and antidepressant effects of a single intranasal dose of ketamine in inpatients during a mood episode in Major Depressive Disorder (MDD) or Bipolar Disorder (BD) with or without comorbid recent abuse of alcohol.
Status: Recruiting
Start date: 2008-05-01
Phase III
Blinded
50 participants
Interventional
To evaluate if naltrexone plus ketamine is effective in reducing depression and alcohol consumption.
Status: Completed
Start date: 2016-1-5
Phase II
Open
5 participants
Interventional
The investigators will compare 3 treatment groups (ketamine plus naltrexone vs. ketamine alone vs. placebo) for treating major depressive disorder (MDD) and alcohol use disorder (AUD) in an 8-week randomized, double-blind, placebo-controlled, between-subjects trial.
Status: Recruiting
Start date: 2015-1-1
Phase I
Blinded
65 participants
Interventional
This open-label trial (n=5) investigates the effects of ketamine (35mg/70kg, 4x over 4 weeks) on those suffering from depression and alcohol dependence simultaneously.
Status: Completed
Start date: 2021-03-01
Phase I
Open
5 participants
Interventional
Find Psychedelic Trials
Browse through all psychedelic trials that have been done or are ongoing. These trials, usually double-blind, placebo-controlled studies, are the core of psychedelic research. The outcome of these trials will determine the future of psychedelics as medicine.
The trials included in our database come from ClinicalTrials.Gov and from the various companies pursuing psychedelics as medicine. Most of the trials have been funded by universities, though companies and governments are currently starting to ramp up their involvement.
